Edit
Oxford Genetics Ltd.
https://www.oxfordgenetics.com/Last activity: 18.03.2025
Active - Reference to OXGENE
Location: United States, Ohio, Oxford
Employees: 51-200
Total raised: $9.85M
Founded date: 2011
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.08.2017 | - | $9.62M | - |
| 30.07.2013 | - | $228.89K | - |
Mentions in press and media 12
| Date | Title | Description |
| 19.03.2025 | WuXi AppTec: A Phoenix Rising in the Pharmaceutical Landscape | WuXi AppTec is on the rise, much like a phoenix emerging from the ashes. The Chinese pharmaceutical services giant has recently forecasted a return to double-digit revenue growth, igniting investor enthusiasm and sending its stock soaring. ... |
| 18.03.2025 | WuXi AppTec Soars After Chinese Drug Services Giant Predicts Double-Digit Revenue Growth | (Yicai) March 18 -- WuXi AppTec's shares rose after the Chinese provider of research and development services to the pharmaceutical sector forecast annual revenue to return to double-digit growth this year after earnings fell last year. WuX... |
| 28.12.2024 | WuXi's Strategic Retreat: Navigating U.S. Restrictions | In the ever-shifting landscape of global business, few stories capture the tension between opportunity and regulation like that of WuXi AppTec. This Chinese pharmaceutical giant is now selling its Advanced Therapies unit, a move that unders... |
| 27.12.2024 | Китайская фармкомпания WuXi продаст подразделение Advanced Therapies на фоне ограничений США | Компания WuXi, наряду с другими китайскими фирмами, оказалась в центре новых законов США, направленных на ограничение их бизнеса в Соединенных Штатах из-за проблем национальной безопасности. В сентябре Палата представителей США приняла зако... |
| 24.12.2024 | China's WuXi to sell Advanced Therapies unit amid US restrictions | China's WuXi to sell Advanced Therapies unit amid US restrictions By ReutersDecember 24, 20248:25 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link The logo of Chinese drug research and developmen... |
| 07.01.2019 | Mercia boosts SMEs with almost £60m invested in 2018 | Mercia invested £59.7million in 2018, with over 90 per cent of the funding going to businesses outside of London and the South East. The figure, up from £48.0million the previous year, highlights Mercia’s role as one of the UK’s most active... |
| 07.08.2018 | Oxford Genetics secures significant multi-million pound contract | Mercia Technologies PLC is pleased to announce that Oxford Genetics (OG) has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community. |
| 22.08.2017 | UK-based bio-engineering firm Oxford Genetics raises £7.5 million | UK-based Oxford Genetics, which specialises in providing bio-engineering services, has raised £7.5 million. The round was led by existing investor Mercia Technologies PLC and Invesco Perpetual. Oxford Genetics offers a range of services rel... |
| 22.08.2017 | Oxford Genetics Secures £7.5M Investment | Oxford Genetics, a UK-based developer of innovative synthetic biology-based technologies for biologics discovery, development and delivery, received a £7.5m investment. Backers included existing investor Mercia Technologies and Invesco Perp... |
| 18.03.2016 | Oxford Genetics becomes latest emerging star to join Mercia Technologies’ portfolio | Mercia Technologies, a Midlands-based investment group building, funding and commercialising technology businesses in the UK, is pleased to announce a new direct investment of up to £2.0 million in Oxford Genetics Ltd. Through its expertise... |
Show more